問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Rheumatology

Division of Dermatology

更新時間：2023-09-19

周吟怡
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周吟怡

List

8Cases

2019-07-19 - 2022-01-01

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    NA

Participate Sites
6Sites

Recruiting6Sites

2020-07-31 - 2024-02-06

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2021-01-01 - 2025-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-11-01 - 2022-06-21

Phase III

A Randomized, Double-Blind, Placebo-Controlled Confirmatory Study of the Safety and Efficacy of ASP015K in Patients with Rheumatoid Arthritis (RA) who Had an Inadequate Response or Intolerance to MTX

  • Condition/Disease

    Rheumatoid Arthritis (RA)

  • Test Drug

    ASP015K

Participate Sites
6Sites

Terminated5Sites

黃春明
China Medical University Hospital-Taipei

未分科

張棋楨
Taipei Medical University Hospital

2015-08-14 - 2017-12-31

Phase II

A multicenter, randomized, double-blind, placebo and active controlled Phase 2b dose-finding study of QGE031 as add-on therapy to investigate the efficacy and safety in patients with Chronic Spontaneous Urticaria (CSU)

  • Condition/Disease

    Chronic Spontaneous Urticaria (CSU)

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

2016-06-01 - 2019-08-31

Phase II

An open label, multicenter, extension study to evaluate the long-term safety of QGE031 240 mg s.c. given every 4 weeks for 52 weeks in Chronic Spontaneous Urticaria patients who completed study CQGE031C2201

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    QGE031

Participate Sites
3Sites

Terminated3Sites

鐘文宏
Linkou Chang Gung Medical Foundation

Division of Dermatology

2018-09-01 - 2022-08-03

Phase III

A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines

  • Condition/Disease

    Chronic Spontaneous Urticaria (CSU)

  • Test Drug

    QGE031/ligelizumab

Participate Sites
3Sites

Recruiting3Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

2020-05-01 - 2023-05-31

Phase III

A Multi-center, Double-blinded and Open-label Extension Study to Evaluate the Efficacy and Safety of Ligelizumab as Retreatment, Self-administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies CQGE031C2302, CQGE031C2303, CQGE031C2202 or CQGE031C1301

  • Condition/Disease

    Chronic Spontaneous Urticaria

  • Test Drug

    QGE031

Participate Sites
3Sites

Not yet recruiting1Sites

Recruiting2Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB